查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1879287

超越传统药丸市场－全球产业规模、份额、趋势、机会及预测，依治疗领域、产品、地区及竞争格局划分，2020-2030年预测

Beyond The Pill Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapeutic Area, By Offerings, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球「超越药物疗法」市场规模将从2024年的2.8244亿美元成长到2030年的4.1644亿美元，复合年增长率达6.69%。该市场涵盖创新数位健康解决方案、服务和智慧设备，旨在超越传统药物干预，提升患者参与度、治疗依从性和整体健康效果。推动该市场扩张的关键因素包括：全球慢性病盛行率不断上升，需要持续管理；对个人化医疗干预的需求日益增长；以及远端监测和人工智慧等领域的持续技术进步。

市场概览
预测期 2026-2030
2024年市场规模 2.8244亿美元
2030年市场规模 4.1644亿美元
2025-2030年复合年增长率 6.69%
成长最快的细分市场 肿瘤学
最大的市场 北美洲

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：客户之声

第五章：全球避孕药市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依治疗领域（糖尿病、肿瘤、心血管疾病、气喘、其他）
    • 按服务项目（服务、监测、援助、资讯、教育）
    • 按地区
    • 按公司（2024 年）
  • 市场地图

第六章：北美避孕药市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第七章：欧洲避孕药市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国家分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区避孕药市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东与非洲避孕药市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东和非洲：国家分析
    • 沙乌地阿拉伯
    • 阿联酋
    • 南非

第十章：南美洲避孕药市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国家分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章：市场动态

  • 司机
  • 挑战

第十二章：市场趋势与发展

  • 併购（如有）
  • 产品发布（如有）
  • 最新进展

第十三章：全球避孕药市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商议价能力
  • 顾客的力量
  • 替代产品的威胁

第十五章：竞争格局

  • F. Hoffmann-La Roche Ltd. (Flatiron Health, Inc.)
  • Otsuka Pharmaceutical Co., Ltd.
  • Amgen, Inc.
  • AstraZeneca PLC
  • Novartis AG
  • Sanofi SA
  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Johnson & Johnson Services Inc.
  • Teva Pharmaceutical Industries Ltd.

第十六章：策略建议

第17章调查会社について・免责事项

简介目录
Product Code: 8071

The Global Beyond The Pill Market will grow from USD 282.44 Million in 2024 to USD 416.44 Million by 2030 at a 6.69% CAGR. The "Global Beyond The Pill Market" encompasses innovative digital health solutions, services, and smart devices that extend beyond traditional pharmaceutical interventions to enhance patient engagement, treatment adherence, and overall health outcomes. Key drivers supporting this market's expansion include the increasing global prevalence of chronic diseases demanding continuous management, a growing imperative for personalized healthcare interventions, and continuous technological advancements in areas like remote monitoring and artificial intelligence.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 282.44 Million
Market Size 2030USD 416.44 Million
CAGR 2025-20306.69%
Fastest Growing SegmentOncology
Largest MarketNorth America

Key Market Drivers

The increasing global burden of chronic diseases represents a primary impetus for the expansion of the "Global Beyond The Pill Market." As populations age and lifestyles evolve, conditions such as diabetes, cardiovascular disease, and chronic respiratory illnesses necessitate continuous management beyond traditional episodic care. These long-term conditions demand solutions that support patient adherence, facilitate remote monitoring, and enable personalized interventions, thereby moving healthcare delivery beyond solely pharmaceutical products. According to the International Diabetes Federation's (IDF) Diabetes Atlas 2025, approximately 589 million adults are living with diabetes worldwide, underscoring the immense and growing patient pool requiring innovative, integrated care models. This persistent and escalating prevalence drives the need for digital health solutions that can effectively integrate into daily life, offering sustained support and improving long-term health outcomes.

Key Market Challenges

The complex and often fragmented global regulatory landscape represents a significant impediment to the growth of the "Global Beyond The Pill Market". This challenge manifests as increased costs and protracted timelines for product development and market access, directly hindering the widespread adoption of innovative digital health solutions. Manufacturers must navigate disparate national and regional requirements, leading to duplicative efforts in testing, documentation, and approval processes.

The financial burden imposed by these regulatory complexities is substantial. According to a MedTech Europe 2024 Regulatory Survey, medical device manufacturers anticipate a 50% increase in maintenance and re-certification costs over a five-year cycle due to evolving regulations. This escalation in operational expenses diminishes investment capacity for research and development into new digital health technologies, effectively slowing the pace of innovation.

Key Market Trends

Strategic Expansion into Solution Provider Models is fundamentally reshaping the "Global Beyond The Pill Market" by shifting the industry focus from standalone product sales to comprehensive, integrated digital health solutions. This trend involves medical technology companies developing ecosystems of devices, software, and supportive services to provide holistic patient management rather than episodic care. According to MedTech Europe's "Facts & Figures 2025" published in September 2025, digital health is rapidly scaling in Europe, driven by a convergence of breakthrough technologies, patient empowerment, and systemic efficiencies within the medical technology sector. This broader strategic emphasis enhances patient engagement and offers continuous support, transforming value creation in healthcare.

Key Market Players

  • F. Hoffmann-La Roche Ltd. (Flatiron Health, Inc.)
  • Otsuka Pharmaceutical Co., Ltd.
  • Amgen, Inc.
  • AstraZeneca PLC
  • Novartis AG
  • Sanofi S.A.
  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Johnson & Johnson Services Inc.
  • Teva Pharmaceutical Industries Ltd.

Report Scope:

In this report, the Global Beyond The Pill Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Beyond The Pill Market , By Therapeutic Area:

  • Diabetes
  • Oncology
  • Cardiovascular Diseases
  • Asthma
  • Others

Beyond The Pill Market , By Offerings:

  • Services
  • Monitoring
  • Assistance
  • Information
  • Education

Beyond The Pill Market , By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Beyond The Pill Market .

Available Customizations:

Global Beyond The Pill Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Beyond The Pill Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapeutic Area (Diabetes, Oncology, Cardiovascular Diseases, Asthma, Others)
    • 5.2.2. By Offerings (Services, Monitoring, Assistance, Information, Education)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Beyond The Pill Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapeutic Area
    • 6.2.2. By Offerings
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Beyond The Pill Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapeutic Area
        • 6.3.1.2.2. By Offerings
    • 6.3.2. Canada Beyond The Pill Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapeutic Area
        • 6.3.2.2.2. By Offerings
    • 6.3.3. Mexico Beyond The Pill Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapeutic Area
        • 6.3.3.2.2. By Offerings

7. Europe Beyond The Pill Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapeutic Area
    • 7.2.2. By Offerings
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Beyond The Pill Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapeutic Area
        • 7.3.1.2.2. By Offerings
    • 7.3.2. France Beyond The Pill Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapeutic Area
        • 7.3.2.2.2. By Offerings
    • 7.3.3. United Kingdom Beyond The Pill Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapeutic Area
        • 7.3.3.2.2. By Offerings
    • 7.3.4. Italy Beyond The Pill Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Therapeutic Area
        • 7.3.4.2.2. By Offerings
    • 7.3.5. Spain Beyond The Pill Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Therapeutic Area
        • 7.3.5.2.2. By Offerings

8. Asia Pacific Beyond The Pill Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapeutic Area
    • 8.2.2. By Offerings
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Beyond The Pill Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapeutic Area
        • 8.3.1.2.2. By Offerings
    • 8.3.2. India Beyond The Pill Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapeutic Area
        • 8.3.2.2.2. By Offerings
    • 8.3.3. Japan Beyond The Pill Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapeutic Area
        • 8.3.3.2.2. By Offerings
    • 8.3.4. South Korea Beyond The Pill Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapeutic Area
        • 8.3.4.2.2. By Offerings
    • 8.3.5. Australia Beyond The Pill Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapeutic Area
        • 8.3.5.2.2. By Offerings

9. Middle East & Africa Beyond The Pill Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapeutic Area
    • 9.2.2. By Offerings
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Beyond The Pill Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapeutic Area
        • 9.3.1.2.2. By Offerings
    • 9.3.2. UAE Beyond The Pill Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapeutic Area
        • 9.3.2.2.2. By Offerings
    • 9.3.3. South Africa Beyond The Pill Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapeutic Area
        • 9.3.3.2.2. By Offerings

10. South America Beyond The Pill Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapeutic Area
    • 10.2.2. By Offerings
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Beyond The Pill Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapeutic Area
        • 10.3.1.2.2. By Offerings
    • 10.3.2. Colombia Beyond The Pill Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapeutic Area
        • 10.3.2.2.2. By Offerings
    • 10.3.3. Argentina Beyond The Pill Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapeutic Area
        • 10.3.3.2.2. By Offerings

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Beyond The Pill Market : SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. F. Hoffmann-La Roche Ltd. (Flatiron Health, Inc.)
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Otsuka Pharmaceutical Co., Ltd.
  • 15.3. Amgen, Inc.
  • 15.4. AstraZeneca PLC
  • 15.5. Novartis AG
  • 15.6. Sanofi S.A.
  • 15.7. Novo Nordisk A/S
  • 15.8. Eli Lilly and Company
  • 15.9. Johnson & Johnson Services Inc.
  • 15.10. Teva Pharmaceutical Industries Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer